Age (y) (median (range)) | 64 (35–87) |
Male sex | 293 (72.7%) |
Viral infection | |
HBsAg positive | 39 (9.6%) |
Anti-HCVAb positive | 336 (83.4%) |
Both positive | 6 (1.5%) |
Both negative | 34 (8.4%) |
Child-Pugh classification | |
Class A | 222 (55.1%) |
Class B | 160 (39.7%) |
Class C | 21 (5.2%) |
Tumour characteristics | |
Size of tumour (cm) | |
<2 | 134 (33.3%) |
2–5 | 234 (58.1%) |
>5 | 35 (8.7%) |
No of nodules | |
Single | 215 (53.3%) |
2–3 | 135 (33.5%) |
>3 | 53 (13.2%) |
Portal invasion, present | 4 (1.0%) |
AFP (ng/ml) | |
<100 | 308 (76.4%) |
100–400 | 58 (14.3%) |
>400 | 37 (9.2%) |
Okuda stage | |
I | 296 (73.4%) |
II | 107 (26.6%) |
III | 0 (0%) |
CLIP score | |
0 | 118 (29.3%) |
1 | 165 (40.9%) |
2 | 98 (24.3%) |
3 | 18 (4.5%) |
4⩽ | 4 (1.0%) |
BCLC staging | |
A1 | 70 (17.4%) |
A2 | 58 (14.4%) |
A3 | 32 (7.9%) |
A4 | 100 (24.8%) |
B | 115 (28.5%) |
C | 7 (1.7%) |
D | 21 (5.2%) |
Treatment modalities | |
PEIT | 363 (90.0%) |
PMCT | 26 (6.5%) |
PEIT + PMCT | 14 (3.5%) |
Combined with TAE | 54 (13.4%) |